[1]孟凡萍,郝 坡,范 慧.甲状腺乳头状癌并发桥本氏甲状腺炎患者BRAF-V600E 基因表达及T 淋巴细胞亚群分析[J].现代检验医学杂志,2020,35(01):32-34.[doi:10.3969/j.issn.1671-7414.2020.01.009]
　MENG Fan-ping,HAO Po,FAN Hui.Expression of BRAF-V600E Gene and Analysis of Lymphocyte Subgroup in Thyroid Papillary Carcinoma Combined with Hashimoto's Thyroiditis[J].Journal of Modern Laboratory Medicine,2020,35(01):32-34.[doi:10.3969/j.issn.1671-7414.2020.01.009]
点击复制

甲状腺乳头状癌并发桥本氏甲状腺炎患者BRAF-V600E 基因表达及T 淋巴细胞亚群分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年01期
页码:
32-34
栏目:
论　　著
出版日期:
2020-02-29

文章信息/Info

Title:
Expression of BRAF-V600E Gene and Analysis of Lymphocyte Subgroup in Thyroid Papillary Carcinoma Combined with Hashimoto's Thyroiditis
文章编号:
1671-7414(2020)01-032-04
作者:
孟凡萍1; 郝 坡2; 范 慧1
(1.重庆三峡中心医院,重庆 404000; 2.重庆三峡医药高等专科学校,重庆 400020)
Author(s):
MENG Fan-ping1; HAO Po2; FAN Hui1
(1.Chongqing Three Gorges Central Hospital Chongqing 404000,China; 2. Chongqing Three GorgesMedical College,Chongqing 400020,China)
关键词:
甲状腺乳头状癌;  桥本氏甲状腺炎;  BRAF V600E基因;  CD4+/CD8+
分类号:
R736.1; R730.43
DOI:
10.3969/j.issn.1671-7414.2020.01.009
文献标志码:
A
摘要:
目的 探讨甲状腺乳头状癌并发桥本氏甲状腺炎BRAF-V600E基因表达及T淋巴细胞亚群的变化。方法 选取2018年9月～2019年8月期间于重庆三峡中心医院就诊的单纯甲状腺乳头状癌患者(PTC 组)45例、单纯桥本氏甲状腺炎(HT组)患者55例、甲状腺乳头状癌并发桥本氏甲状腺炎患者(PTC-HT组)42例,以健康体检者(NC组)50例为对照。观察三组研究对象的BRAF -V600E基因表达及CD4+T,CD8+T,CD4+/CD8+的变化。结果 PTC 组患者BRAF- V600E突变率48.15%,HT组1.81%,PTC-HT组66.67%,NC组未见BRAF-V600E突变; 三个观察组CD8+T均比NC组显著升高,CD4+均比NC组显著降低,差异均有统计学意义(P<0.05),但PTC组患者CD4+显著低于HT组和PTC-HT组,PTC-HT组CD8+又显著低于HT组,差异均有统计学意义(均P<0.05)。三个观察组CD4+/CD8+均比NC组显著升高显著下降,差异均有统计学意义(P<0.05)。结论 与PTC组相比,BRAF- V600E在PTC-HT组患者表达率更高,PTC,PTC-HT和HT患者T淋巴细胞亚群均分化异常,机体存在免疫功能障碍,尤以PTC为甚。
Abstract:
Objective To investigate the expression of BRAF-V600E gene and changes of T lymphocyte subsets in thyroid papillary carcinoma combined with Hashimoto's thyroiditis. Methods From September 2018 to August 2019 in Chongqing Three Gorges Central Hospital, 45 patients with simple papillary thyroid cancer(PTC group), 55 patients with Hashimoto's thyroiditis(HT group), 42 patients with papillary thyroid cancer and Hashimoto's thyroiditis(PTC-HT group), and 50 healthy subjects(NC group)were selected as controls. The BRAF-V600E gene expression and the changes of CD4+T, CD8+T and CD4+/CD8+in three groups were observed.Results The mutation rate of BRAF-V600E in the PTC group was 48.15 %, HT group was 1.81 %, PTC-HT group was 66.67 %, and the BRAF-V600E mutation was not observed in the NC group.The three observation groups CD8+ was all higher than the NC group, CD4+ significanlly decreased compared with NC group, the differences were statistically significant(all P<0.05),but the PTC group patients CD4+ were significantly lower than the HT and PTC-HT groups CD4+ in PTC-HT group was significantly lower than the HT group,the differentes were statistically significant(all P<0.05). The three observation groups had a significant decrease in CD4+/CD8+ compared to the NC group,the differences wree statistically significant(t/x2 all P<0.05).Conclusion Compared with PTC, BRAF-V600E had a higher expression rate in PTC-HT patients and the difference was significant, PTC, PTC-HT and HT patients had abnormal differentiation of T lymphocyte subgroups, and the body had immune dysfunction, especially PTC.

参考文献/References:

[1] HE Yayi, LIU Shu, GUO Hui, et al. Incidental finding of papillary thyroid carcinoma with BRAFV600E mutation in a patient with coexistent primary hyperparathyroidism and Graves'hyperthyroidism[J]. BMJ Case Reports, 2014, 2014: pii:bcr2013203436.
[2] PYZIK A, GRYWALSKA E, MATYJASZEK-MATUSZEK B, et al. Immune disorders in Hashimoto's thyroiditis: what do we know so far [J]. Journal of Immunology Research, 2015,2015: 979167.
[3] HU Shiqian, RAYMAN M P. Multiple nutritional factors and the risk of Hashimoto's thyroiditis[J]. Thyroid, 2017, 27(5): 597-610.
[4] UHLIAROVA B, HAJTMAN A. Hashimoto's thyroiditis - an independent risk factor for papillary carcinoma [J]. Braz J Otorhinolaryngol,2018,84(6):729-735.
[5] NOURELDINES I, TUFANO R P. Association of Hashimoto's thyroiditis and thyroid cancer[J]. Curr Opin Oncol, 2015,27(1):21-25.
[6] 史敏,郭晓波,李思远,等.结直肠癌患者组织中K-ras和BRAF基因突变与不同病理特征的相关性分析[J].现代检验医学杂志,2018,33(3):27-30. SHI Min,GUO Xiaobo,LI Siyuan,et al. Correlation of K-ras and BRAF mutations with pathological features in patients with colorectal cancer[J]. Journal of Morden Laboratory Medicine,2018,33(3):27-30.
[7] ROCCA B J, AMBROSIO M R, GINORI A, et al. Detection of BRAFV600E mutation on papillary thyroid carcinoma and metastatic malignant melanoma by Fine-Needle aspiration cytology: how genetic testing May drive toward personalized medicine[J]. Diagnostic Cytopathology, 2014, 42(10): 877-879.
[8] KIM J K, SEONG C Y, BAE I E, et al. Comparison of immunohistochemistry and direct sequencing methods for identification of the BRAF(V600E)mutation in papillary thyroid carcinoma[J]. Annals of Surgical Oncology, 2018, 25(6): 1775-1781.
[9] HAN Litao, HU Jiaqian, MA Ben, et al. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis[J]. Diagnostic Pathology, 2019, 14(1): 52.
[10] PILLI T, TOTI P, OCCHINI R, et al. Chronic lymphocytic thyroiditis(CLT)has a positive prognostic value in papillary thyroid cancer(PTC)patients: the potential key role of Foxp3+T lymphocytes[J]. Journal of Endocrinological Investigation, 2018, 41(6): 703-709.
[11] YANG S W, KANG S H, KIM K R, et al. Do helper T cell subtypes in lymphocytic thyroiditis play a role in the antitumor effect[J].J Pathol Transl Med, 2016, 50(5): 377-384.
[12] ZIVANCEVIC S S, MIHALJEVIC O, MAJSTOROVIC I, et al. Cytokine production in patients with papillary thyroid cancer and associated autommune autoimmune Hashimoto thyroiditis[J]. Cancer Immunol Immunother.2015, 64(8): 1011-1019.
[13] LIU Y, YUN X, GAO M, et al. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis[J]. Clinical & Translational Oncology, 2015, 17(4): 274-280.

相似文献/References:

[1]李桂荣,赵清侠a,宋 斌b,等.miR-221与miR-222在甲状腺乳头状癌组织中的表达及临床意义[J].现代检验医学杂志,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
　LI Gui-rong,ZHAO Qing-xiaa,SONG Binb,et al.Expression of miR-221 and miR-222 in Papillary Thyroid Carcinoma Tissues and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
[2]王　玲,王　健,赵寅生,等.甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J].现代检验医学杂志,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
　WANG Ling,WANG Jian,ZHAO Yin-sheng,et al.Clinical Application Value of Serum Thyrotropin Level and Tissue Thyrotropin Receptor Detection in Patients with Thyroid Papillary Carcinoma[J].Journal of Modern Laboratory Medicine,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
[3]宋晓龙,宋 宇,魏 龙,等.血清TK1，TSH，TG，TGAb 检测联合TI RADS 分类在甲状腺乳头状癌早期筛查中的应用价值[J].现代检验医学杂志,2022,37(04):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
　SONG Xiao-long,SONG Yu,WEI Long,et al.Clinical Value of Serum TK1, TSH, TG and TGAb Detection Combined with TI-RADS Classification in Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(01):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
[4]宋晓龙,魏 龙,秦晋铝,等.甲状腺乳头状癌患者术前血清TK1 表达水平联合甲状腺超声特征构建中央区淋巴结转移预测模型及验证[J].现代检验医学杂志,2023,38(01):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
　SONG Xiao-long,WEI Long,QIN Jin-lü,et al.Construction and Validation of Prediction Model of Central Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma Based on Preoperative Serum TK1 Expression Level and Thyroid Ultrasound Features[J].Journal of Modern Laboratory Medicine,2023,38(01):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
[5]刘 星,霍占江.甲状腺乳头状癌组织中galecti-3 与miR-375 水平表达意义及相关性研究[J].现代检验医学杂志,2023,38(01):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
　LIU Xing,HUO Zhan-jiang.Expression Significance and Correlation of galectin-3 and miR-375 in Papillary Thyroid Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2023,38(01):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
[6]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[7]薛思军a,涂霁韬b.甲状腺乳头状癌组织中miR-137 水平表达及相关实验研究[J].现代检验医学杂志,2023,38(04):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
　XUE Sijuna,TU Jitaob.Expression of miR-137 in Papillary Thyroid Carcinoma Tissue and Its Related Experimental Study[J].Journal of Modern Laboratory Medicine,2023,38(01):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
[8]周 钧a,汪庭军b,唐 珍a.甲状腺乳头状癌患者血清EGR1/2 mRNA 水平检测在临床早期实验诊断中的价值研究[J].现代检验医学杂志,2023,38(05):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]
　ZHOU Juna,WANG Tingjunb,TANG Zhena.Value of Serum EGR1/2 mRNA Detection in Early Clinical Diagnosis of Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(01):93.[doi:10.3969/j.issn.1671-7414.2023.05.018]

备注/Memo

备注/Memo:
基金项目:重庆市自然科学基金面上项目(重庆市科技局,cstc2019jcyj-msxmX0122)。 作者简介:孟凡萍(1980-),女,医学博士,副主任检验师,研究方向:脂代谢和胰岛素抵抗,E-mail:63405353@qq.com。 通讯作者:郝坡(1979-),男,医学硕士,副教授,研究方向:内分泌分子生物学检验,E-mail:hpo1979@126.com。收稿日期:2019-09-06 修回日期:2019-09-30
更新日期/Last Update: 2020-03-30